Possibility of tepotinib to treat other cancers associated with MET mutations

Tepotinib is an oral selective MET inhibitor that mainly targets MET exon 14 skipping mutation (MET exon 14 skipping Non-small cell lung cancer (NSCLC) caused by mutation). In clinical practice, tepotinib has shown significant efficacy against this specific mutation, including tumor shrinkage, delaying disease progression, and improving patient quality of life. The core of this therapeutic mechanism is to block the MET signaling pathway, thereby inhibiting the proliferation and metastasis of cancer cells. Based on this mechanism, scientists have begun to explore the potential application of tepotinib in other types of MET mutation-related cancers.

Some studies have shown that MET mutations are not only present in lung cancer, but also in various tumor types such as gastric cancer, hepatocellular carcinoma, breast cancer and thyroid cancer. Tepotinib is expected to inhibit the abnormal proliferation of these tumor cells by selectively inhibiting MET kinase activity. For example, in patients with hepatocellular carcinoma, tepotinib may slow tumor progression by blocking signaling pathways if MET gene amplification or activating mutations are present. Similarly, for some patients with gastric cancer and breast cancer, abnormal MET signal may also become a driving factor, providing new ideas for targeted therapy.

Currently, clinical research on tepotinib for the treatment of other MET mutation-related cancers is still in its early stages. Several international multicenter clinical trials are evaluating its efficacy and safety in different tumor types. For example, some Phase II trials have been launched in patients with gastric cancer and liver cancer to observe the drug's objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS). The preliminary results of these studies show that some patients have indeed achieved considerable tumor response, providing a basis for the expansion of the indications of tepotinib.

Overall, tepotinib has shown certain therapeutic potential in MET mutation-related cancers other than non-small cell lung cancer. Although it has not yet received formal indication approval, its application scope may gradually expand as clinical trial data accumulates. In the future, MET will be screened out through precise molecular testing.For patients with abnormal tumors, tepotinib is expected to become a targeted treatment option for a variety of solid tumors, providing new treatment options for more cancer patients, while promoting the development of MET targeted therapy in the field of cancer.

Reference link:https://www.drugs.com